Want to see ADAPY full AI Analyst Report?
Adaptimmune Therapeutics (ADAPY) Stock Statistics & Valuation Metrics
Total Valuation
Adaptimmune Therapeutics has a market cap or net worth of $6.10M. The enterprise value is $85.92M.
- Market Cap
- $6.10M
- Enterprise Value
- $85.92M
Share Statistics
Adaptimmune Therapeutics has 265,051,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 265,051,600
- Owned by Insiders
- ―
- Owned by Institutions
- 0.23%
Financial Efficiency
Adaptimmune Therapeutics’s return on equity (ROE) is -5.98 and return on invested capital (ROIC) is -36.03%.
- Return on Equity (ROE)
- -5.98
- Return on Assets (ROA)
- -0.29
- Return on Invested Capital (ROIC)
- -36.03%
- Return on Capital Employed (ROCE)
- -0.38
- Revenue Per Employee
- 654.53K
- Profits Per Employee
- -260.35K
- Employee Count
- 272
- Asset Turnover
- 0.72
- Inventory Turnover
- 0.01
Valuation Ratios
The current PE Ratio of Adaptimmune Therapeutics is -0.08. Adaptimmune Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- -0.08
- PS Ratio
- 1.03
- PB Ratio
- 0.06
- Price to FCF
- -0.08
- Price to Operating Cash Flow
- -0.03
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Adaptimmune Therapeutics had revenue of 178.03M and earned -70.81M in profits. Earnings per share was -0.28.
- Revenue
- 178.03M
- Gross Profit
- 177.96M
- Operating Income
- -68.76M
- Pretax Income
- -67.27M
- Net Income
- -70.81M
- EBITDA
- -52.66M
- Earnings Per Share (EPS)
- -0.28
Cash Flow
In the last 12 months, operating cash flow was -190.03M and capital expenditures -2.89M, giving a free cash flow of -191.71M billion.
- Operating Cash Flow
- -190.03M
- Free Cash Flow
- -191.71M
- Free Cash Flow per Share
- -0.90
Dividends & Yields
Adaptimmune Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1245.47%
- Earnings Yield
- 1304.35%
Stock Price Statistics
- Beta
- -7.98
- 52-Week Price Change
- -54.00%
- 50-Day Moving Average
- 0.03
- 200-Day Moving Average
- 0.03
- Relative Strength Index (RSI)
- 42.76
- Average Volume (3m)
- 187.90K
Important Dates
Adaptimmune Therapeutics upcoming earnings date is ―, TBA (Not Confirmed).
- Last Earnings Date
- Aug 12, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Adaptimmune Therapeutics as a current ratio of 2.92, with Debt / Equity ratio of 626.29%
- Current Ratio
- 2.92
- Quick Ratio
- 2.80
- Debt to Market Cap
- 0.40
- Net Debt to EBITDA
- 0.32
- Interest Coverage Ratio
- -20.54
Taxes
In the past 12 months, Adaptimmune Therapeutics has paid 3.58M in taxes.
- Income Tax
- 3.58M
- Effective Tax Rate
- -0.05
Enterprise Valuation
Adaptimmune Therapeutics EV to EBITDA ratio is 0.10, with an EV/FCF ratio of 0.08.
- EV to Sales
- -0.97
- EV to EBITDA
- 0.10
- EV to Free Cash Flow
- 0.08
- EV to Operating Cash Flow
- 0.08
Balance Sheet
Adaptimmune Therapeutics has $26.06M in cash and marketable securities with $48.68M in debt, giving a net cash position of -$22.62M billion.
- Cash & Marketable Securities
- $26.06M
- Total Debt
- $48.68M
- Net Cash
- -$22.62M
- Net Cash Per Share
- -$0.09
- Tangible Book Value Per Share
- -$0.28
Margins
Gross margin is 100.00%, with operating margin of -1225.05%, and net profit margin of 425.49%.
- Gross Margin
- 100.00%
- Operating Margin
- -1225.05%
- Pretax Margin
- -1316.78%
- Net Profit Margin
- 425.49%
- EBITDA Margin
- -970.48%
- EBIT Margin
- -1082.41%
Scores
- Smart Score
- ―
- AI Score
- 44
